• The technology described in this briefing is eXroid. It uses electrotherapy to shrink internal haemorrhoids.

  • The innovative aspects are the treatment does not need general, regional or local anaesthesia.

  • The intended place in therapy would be as instead of standard care treatments (such as rubber band ligation, injection sclerotherapy, bipolar diathermy, haemorrhoidectomy or stapled haemorrhoidectomy) in people with internal haemorrhoids.

  • The main points from the evidence summarised in this briefing are from 2 non-comparative studies including 157 adults in hospital. They show that eXroid can treat internal haemorrhoids effectively without any complications.

  • Key uncertainties around the evidence or technology are that there is very limited evidence comparing eXroid with any other treatments.

  • The cost of eXroid is £745 per treatment. The company does not sell the device but negotiates treatment fees with clinicians and clinics. The resource impact would likely be similar or less than standard care, if surgery is avoided and the haemorrhoids are treated in 1 session. However, there is no evidence on the resource impact of the technology.